These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25264941)

  • 1. Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.
    Ma Y; Tomita Y; Preet A; Clarke R; Englund E; Grindrod S; Nathan S; De Oliveira E; Brown ML; Rosen EM
    Mol Endocrinol; 2014 Dec; 28(12):1971-86. PubMed ID: 25264941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
    Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
    Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
    Zhang X; Ding L; Kang L; Wang ZY
    PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
    Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
    Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
    Liu S; Han SJ; Smith CL
    Mol Pharmacol; 2013 May; 83(5):1066-77. PubMed ID: 23462505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
    Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogens suppress effects of transforming growth factor-β in breast cancer cells via the signaling axis estrogen receptor-α and Y-box Binding Protein-1.
    Popp SL; Joffroy C; Stope MB; Buck MB; Fritz P; Knabbe C
    Anticancer Res; 2013 Jun; 33(6):2473-80. PubMed ID: 23749898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
    Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
    Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
    Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
    Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
    ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.